Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTN | P21246 | 1/20 | 0.40 |
| ▸ | MDK | P21741 | 1/20 | 0.40 |
| ▸ | BDNF | P23560 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CD69 | Q07108 | 1/20 | 0.37 |
| ▸ | HK1 | P19367 | 1/20 | 0.37 |
| ▸ | HK2 | P52789 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17689074 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL22362645 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL15966272 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL20474503 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL15966248 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL23631128 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL15965653 | 1.00 | MAPK1 (0.45) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| Phosphoric Acid SCHEMBL27756060 | 0.95 | AMDHD2 (0.46) | MAPK1AMDHD2ALDH1A1THRBLMNA | |
| SCHEMBL20415021 | 0.88 | BDNF (0.38) | MAPK1ALDH1A1THRBPTNMDK | |
| SCHEMBL16566075 | 0.87 | ALDH1A1 (0.40) | MAPK1ALDH1A1THRBPTNMDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4401753-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND ENHANCING IMMUNE CHECKPOINT INHIBITOR EFFICACY | Gnubiotics Sciences SA (CH) | 2024-07-24 | — | — | EP | claimed |
| WO-2023041979-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND ENHANCING IMMUNE CHECKPOINT INHIBITOR EFFICACY | GNUBIOTICS SCIENCES SA (CH) | 2023-03-23 | — | — | WO | claimed |
| WO-2023037165-A1 | METHODS AND COMPOSITIONS FOR REDUCING NEUTROPHILS OR NEUTROPHIL INFILTRATION AT THE SITE OF DISEASE | GNUBIOTICS SCIENCES SA (CH) | 2023-03-16 | — | — | WO | claimed |
| US-12630593-B2 | Method of killing leukemia cells by administration of recombinant'Y3 proteins | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-19 | — | — | US | disclosed |
| US-20240382560-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND ENHANCING IMMUNE CHECKPOINT INHIBITOR EFFICACY | GNUBIOTICS SCIENCES SA (CH) | 2024-11-21 | — | — | US | disclosed |
| EP-4401753-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND ENHANCING IMMUNE CHECKPOINT INHIBITOR EFFICACY | Gnubiotics Sciences SA (CH) | 2024-07-24 | — | — | EP | disclosed |
| US-20230272019-A1 | FUNGAL GLYCAN BINDING PROTEIN WHICH POSSESSES ANTIVIRAL AND ANTICANCER ACTIVITY | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-08-31 | — | — | US | disclosed |
| WO-2023041979-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND ENHANCING IMMUNE CHECKPOINT INHIBITOR EFFICACY | GNUBIOTICS SCIENCES SA (CH) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023037165-A1 | METHODS AND COMPOSITIONS FOR REDUCING NEUTROPHILS OR NEUTROPHIL INFILTRATION AT THE SITE OF DISEASE | GNUBIOTICS SCIENCES SA (CH) | 2023-03-16 | — | — | WO | disclosed |
| US-11512119-B2 | Fungal glycan binding protein which possesses antiviral and anticancer activity | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630593-B2 | Method of killing leukemia cells by administration of recombinant'Y3 proteins | L3MBTL3, CHI3L1, BCL3 | MAPK1 1568/4885AMDHD2 3196/4885ALDH1A1 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.